☆ 4.6 Article

Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study

BRITISH JOURNAL OF DERMATOLOGY (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Letter Dermatology

Bullous pemphigoid after anti-programmed death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes

Caroline A. Nelson et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2022)

添加到收藏夹

Review Dermatology

Lichen Planus Pemphigoides Associated With PD-1 and PD-L1 Inhibitors: A Case Series and Review of the Literature

Margaret M. Boyle et al.

Summary: Dermatologic toxicities, particularly lichen planus pemphigoides (LPP), have been widely reported in patients receiving immune checkpoint inhibitors. Prompt recognition and treatment are important. This study presented the clinical, histopathologic, and immunofluorescence findings of 3 patients with LPP and reviewed 7 previously reported cases. Diagnosis of immunotherapy-induced LPP occurred at a median time of 24.4 weeks and clinical manifestations included skin lesions and oral involvement.

AMERICAN JOURNAL OF DERMATOPATHOLOGY (2022)

添加到收藏夹

Review Dermatology

Association of Bullous Pemphigoid With Immune Checkpoint Inhibitor Therapy in Patients With Cancer A Systematic Review

Maria S. Asdourian et al.

Summary: This systematic review examines the risk factors, clinical presentation, diagnostic findings, treatments, and outcomes of immune checkpoint inhibitor-induced bullous pemphigoid (ICI-BP) in cancer patients based on current literature. The study suggests that ICI-BP poses therapeutic challenges and further research is needed for early recognition, diagnosis, and targeted treatment options to improve patient outcomes.

JAMA DERMATOLOGY (2022)

添加到收藏夹

Article Dermatology

Incidence, prevalence and mortality of bullous pemphigoid in England 1998-2017: a population-based cohort study

M. S. M. Persson et al.

Summary: The study found an increase in the incidence rate of BP in England, especially among elderly men. The burden of disease in the elderly population is substantial, and mortality is significantly higher in the first 2 years after a BP diagnosis.

BRITISH JOURNAL OF DERMATOLOGY (2021)

添加到收藏夹

Review Dermatology

Cutaneous toxicities in patients with melanoma receiving checkpoint inhibitor therapy: a retrospective review. The experience of a single large specialist institution

C. L. Edwards et al.

Summary: Cutaneous toxicity occurs in 24% of melanoma patients receiving CPI therapy, but is generally manageable, with fewer than 5% of patients discontinuing treatment.

CLINICAL AND EXPERIMENTAL DERMATOLOGY (2021)

添加到收藏夹

Article Oncology

Delayed immune-related adverse events with an PD-1-based immunotherapy in melanoma

C. N. Owen et al.

Summary: This study revealed that delayed irAEs occur in approximately 5.3% of patients receiving anti-PD-1-based therapy, with common manifestations including colitis, rash, and pneumonitis. Some patients may experience severe symptoms and even death as a result of delayed irAEs.

ANNALS OF ONCOLOGY (2021)

添加到收藏夹

Letter Dermatology

Clinical, biological and histological characteristics of bullous pemphigoid associated with anti-PD-1/PD-L1 therapy: A national retrospective study

C. Juzot et al.

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2021)

添加到收藏夹

Article Medicine, General & Internal

Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma

Se Ryeong Jang et al.

Summary: This study examined the effectiveness of cancer immunotherapy in male and female patients with advanced melanoma and found that women may not benefit as much from combination ICIs as men would. Tumor mutation burden or estrogen level may serve as important biomarkers associated with ICI response in metastatic melanoma.

JAMA NETWORK OPEN (2021)

添加到收藏夹

Review Dermatology

Stevens-Johnson syndrome and toxic epidermal necrolysis-like reactions to checkpoint inhibitors: a systematic review

Nolan J. Maloney et al.

INTERNATIONAL JOURNAL OF DERMATOLOGY (2020)

添加到收藏夹

Editorial Material Dermatology

Recent Advances in Understanding Pemphigus and Bullous Pemphigoid

Christoph M. Hammers et al.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2020)

添加到收藏夹

Article Multidisciplinary Sciences

Sex-associated molecular differences for cancer immunotherapy

Youqiong Ye et al.

NATURE COMMUNICATIONS (2020)

添加到收藏夹

Book Review Oncology

Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications

Karla A. Lee et al.

EUROPEAN JOURNAL OF CANCER (2020)

添加到收藏夹

Article Oncology

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

Paolo A. Ascierto et al.

LANCET ONCOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

J. Larkin et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Pathology

BRAF V600 Mutational Status in Melanoma Correlates with Cytologic Features in Fine-Needle Aspirate Specimens

Paul J. Lee et al.

ACTA CYTOLOGICA (2019)

添加到收藏夹

Review Dermatology

A review of bullous pemphigoid associated with PD-1 and PD-L1 inhibitors

Adriana T. Lopez et al.

INTERNATIONAL JOURNAL OF DERMATOLOGY (2018)

添加到收藏夹

Article Dermatology

Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: A retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy

Jacob Siegel et al.

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)

添加到收藏夹

Review Oncology

A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management

Adriana T. Lopez et al.

ONCOLOGIST (2018)

添加到收藏夹

Review Oncology

Anti-programmed cell death-1 therapy-associated bullous disorders: a systematic review of the literature

Cathy Yunjia Zhao et al.

MELANOMA RESEARCH (2018)

添加到收藏夹

Review Medicine, General & Internal

The Growing Incidence of Bullous Pemphigoid: Overview and Potential Explanations

Khalaf Kridin et al.

FRONTIERS IN MEDICINE (2018)

添加到收藏夹

Review Oncology

CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition

Elizabeth I. Buchbinder et al.

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)

添加到收藏夹

Article Dermatology

Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions

George Jour et al.

JOURNAL OF CUTANEOUS PATHOLOGY (2016)

添加到收藏夹

Article Oncology

Autoimmune Bullous Skin Disorders with Immune Checkpoint Inhibitors Targeting PD-1 and PD-L1

Jarushka Naidoo et al.

CANCER IMMUNOLOGY RESEARCH (2016)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.